Af­ter pa­tient death, FDA slaps clin­i­cal hold on ear­ly-stage AML tri­al study­ing 2sev­en­ty bio as­set

A Seat­tle Chil­dren’s Hos­pi­tal-led tri­al study­ing 2sev­en­ty bio’s CD33-tar­get­ed CAR-T cell ther­a­py, SC-DAR­IC33, in acute myeloid leukemia has been put on clin­i­cal hold by the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER